Iron supplementation does not affect cell proliferation or aberrant crypt foci development in the colon of sprague-dawley rats.
It has been suggested that high iron stores enhance colon carcinogenesis. The effect of high dietary iron (Fe) on indices of iron, copper (Cu) and manganese (Mn) status, lipid peroxidation using the thiobarbituric acid reactive substances assay, superoxide dismutase, glutathione peroxidase, glutathione transferase and ceruloplasmin activities, cell proliferation and development of preneoplastic lesions known as aberrant crypt foci (ACF) in rat colon was examined using a 3 x 2 factorial design. Male weanling Sprague-Dawley rats were fed adequate (AFe; 45 mg Fe/kg diet), moderately high (MHFe; 225 mg Fe/kg diet) and high (HFe; 450 mg Fe/kg diet) dietary Fe for 2.5 wk, then treated with azoxymethane (AOM; 2 injections, 1 wk apart; total dose 30 mg/kg body weight) or saline (n = 14-15 per group). Dietary treatment continued for another 6 wk after the second AOM dose. At the time of AOM injection, colon Fe concentrations were one- and threefold higher for MHFe and HFe rats, respectively, than for AFe rats. It was proposed that high dietary Fe would adversely affect Cu and Mn status, resulting in impaired antioxidant enzyme activity. However, neither indices of Cu and Mn status nor colonic mucosal antioxidant enzyme activities were affected by dietary Fe except for plasma ceruloplasmin activity, which was slightly lower in rats fed high iron diets than in rats fed adequate iron diets (P < 0.01). Dietary Fe had no significant effect on colonic mucosal lipid peroxidation, cell proliferation or ACF development. In conclusion, our findings suggest that dietary Fe concentrations that are approximately 5 and 10 times adequate do not enhance oxidative stress, cell proliferation and ACF development in the colon of rats.
Soyars
K E
KE
Department of Foods and Nutrition, The University of Georgia, Athens, GA 30602, USA.
Fischer
J G
JG
D000818:Animals; D001397:Azoxymethane / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D003106:Colon / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D003300:Copper / Q000378:metabolism; D004032:Diet; D006400:Hematocrit; D007413:Intestinal Mucosa / Q000378:metabolism; D007501:Iron / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D008054:Lipid Peroxides / Q000378:metabolism; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects; D008297:Male; D008345:Manganese / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010088:Oxidoreductases / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D002273:Carcinogens; D008054:Lipid Peroxides; D008345:Manganese; D003300:Copper; D007501:Iron; D010088:Oxidoreductases; D001397:Azoxymethane